Pilot trial suggests structured support may help limit weight regain after GLP-1 treatment
Glucagon-like peptide-1 (GLP-1) receptor agonists are effective treatments for obesity, but discontinuation is common due to cost, insurance coverage limitations, side effects, patient preference and other factors—and often leads to rapid weight regain. Results from a pilot randomized trial, published in Obesity Science & Practice, suggest that structured support may attenuate early weight gain…
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
A future worth building. What to expect in the new issue of Positive News magazine
United Kingdom
-
Here's the latest sticker shock: Borrowing for a mortgage -- or a car
United States
-
Mitochondrial DNA levels reveal links to tumor growth and chemotherapy-related gene activity
United Kingdom
-
Good News in History, October 7
United Kingdom
-
As femtosecond lasers find new medical uses, Lithuanian manufacturer bets on scale to meet demand
United Kingdom
-
A new way to fight gum disease without wiping out good bacteria
United States
-
Statins may lower glaucoma risk and reduce treatment needs
United Kingdom
-
Study links pregnancy complications to future heart and kidney disease
United Kingdom